

**Experiment Number:** 03038 - 04  
**Test Type:** CHRONIC  
**Route:** DOSED WATER  
**Species/Strain:** MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**

Sodium Tungstate Dihydrate

**CAS Number:** 10213-10-2

**Date Report Requested:** 06/26/2019

**Time Report Requested:** 10:46:08

**First Dose M/F:** 01/17/12 / 01/16/12

**Lab:** BAT

Final Version 2

**NTP Study Number:** C03038  
**Lock Date:** 05/25/2016  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 3.0.2.3\_002  
**PWG Approval Date:** NONE

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE MALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
<b>Disposition Summary</b>				
Animals Initially In Study	50	50	50	50
Early Deaths				
Accidentally Killed	1			
Moribund Sacrifice	5	3	4	5
Natural Death	18	16	9	9
Survivors				
Moribund Sacrifice				1
Natural Death			2	
Terminal Sacrifice	26	31	35	35
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Lymphoma Malignant	1 (2%)			
Gallbladder	(48)	(47)	(50)	(49)
Lymphoma Malignant			2 (4%)	
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(49)	(50)	(50)	(50)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Lymphoma Malignant	1 (2%)			
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Carcinoma			2 (4%)	
Lymphoma Malignant	1 (2%)		2 (4%)	
Liver	(50)	(50)	(50)	(50)
Cholangiocarcinoma	1 (2%)	2 (4%)		
Hemangioma	1 (2%)			1 (2%)
Hemangiosarcoma	2 (4%)	3 (6%)	3 (6%)	1 (2%)
Hepatoblastoma	4 (8%)	2 (4%)	2 (4%)	
Hepatoblastoma, Multiple			1 (2%)	
Hepatocellular Adenoma	11 (22%)	12 (24%)	16 (32%)	10 (20%)
Hepatocellular Adenoma, Multiple	15 (30%)	13 (26%)	13 (26%)	12 (24%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE MALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Hepatocellular Carcinoma	15 (30%)	14 (28%)	8 (16%)	13 (26%)
Hepatocellular Carcinoma, Multiple		6 (12%)	4 (8%)	1 (2%)
Hepatocholangiocarcinoma		1 (2%)		1 (2%)
Histiocytic Sarcoma				1 (2%)
Lymphoma Malignant	3 (6%)		3 (6%)	
Mesentery	(8)	(3)	(6)	(4)
Hemangiosarcoma	1 (13%)			
Hepatocholangiocarcinoma, Metastatic, Liver				1 (25%)
Lymphoma Malignant	2 (25%)		2 (33%)	
Oral Mucosa	(0)	(1)	(0)	(0)
Pancreas	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Lymphoma Malignant	1 (2%)		3 (6%)	
Salivary Glands	(50)	(50)	(50)	(50)
Lymphoma Malignant	2 (4%)		1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(50)
Lymphoma Malignant	1 (2%)		1 (2%)	
Mast Cell Tumor Malignant	1 (2%)			
Stomach, Glandular	(50)	(50)	(50)	(50)
Lymphoma Malignant	1 (2%)		1 (2%)	
Tooth	(42)	(33)	(44)	(35)
Odontoma	1 (2%)	2 (6%)	1 (2%)	

**CARDIOVASCULAR SYSTEM**

Blood Vessel	(49)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Lymphoma Malignant			1 (2%)	
Aorta, Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Hemangioma		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Lymphoma Malignant	1 (2%)		2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 03038 - 04  
**Test Type:** CHRONIC  
**Route:** DOSED WATER  
**Species/Strain:** MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
**CAS Number:** 10213-10-2

**Date Report Requested:** 06/26/2019  
**Time Report Requested:** 10:46:08  
**First Dose M/F:** 01/17/12 / 01/16/12  
**Lab:** BAT

B6C3F1/N MICE MALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Atrium, Hemangiosarcoma		1 (2%)		
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Lymphoma Malignant	2 (4%)		1 (2%)	
Bilateral, Subcapsular, Adenoma, Multiple	1 (2%)			
Subcapsular, Adenoma		2 (4%)	1 (2%)	1 (2%)
Adrenal Medulla	(49)	(50)	(48)	(50)
Pheochromocytoma Benign		2 (4%)		
Pheochromocytoma Malignant				1 (2%)
Islets, Pancreatic	(47)	(50)	(49)	(50)
Adenoma	1 (2%)		3 (6%)	1 (2%)
Lymphoma Malignant			1 (2%)	
Parathyroid Gland	(44)	(43)	(48)	(43)
Pituitary Gland	(48)	(50)	(49)	(50)
Schwannoma Malignant, Metastatic, Spinal Cord	1 (2%)			
Pars Distalis, Adenoma				1 (2%)
Thyroid Gland	(50)	(49)	(50)	(50)
Follicular Cell, Adenoma			2 (4%)	

<b>GENERAL BODY SYSTEM</b>				
None				

<b>GENITAL SYSTEM</b>				
Coagulating Gland	(0)	(0)	(1)	(0)
Epididymis	(50)	(49)	(50)	(50)
Hemangioma		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Lymphoma Malignant	2 (4%)		2 (4%)	
Preputial Gland	(49)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE MALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Lymphoma Malignant	2 (4%)		1 (2%)	
Prostate	(50)	(50)	(50)	(50)
Lymphoma Malignant	3 (6%)		2 (4%)	
Seminal Vesicle	(50)	(50)	(50)	(50)
Carcinoma				1 (2%)
Lymphoma Malignant	1 (2%)		1 (2%)	
Testis	(50)	(50)	(50)	(50)
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma	2 (4%)	2 (4%)	1 (2%)	
Histiocytic Sarcoma		1 (2%)		
Lymphoma Malignant	3 (6%)		5 (10%)	
Mast Cell Tumor Malignant	1 (2%)			
Schwannoma Malignant, Metastatic, Spinal Cord	1 (2%)			
Lymph Node	(3)	(4)	(6)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (25%)		
Hemangiosarcoma			1 (17%)	
Hepatocellular Carcinoma, Metastatic, Liver		1 (25%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (25%)		1 (100%)
Lymphoma Malignant	2 (67%)		5 (83%)	
Lymph Node, Mandibular	(48)	(50)	(49)	(48)
Carcinoma, Metastatic, Harderian Gland			1 (2%)	
Lymphoma Malignant	2 (4%)		3 (6%)	
Mast Cell Tumor Malignant	1 (2%)			
Lymph Node, Mesenteric	(50)	(46)	(48)	(48)
Hemangiosarcoma			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Histiocytic Sarcoma				1 (2%)
Lymphoma Malignant	5 (10%)	1 (2%)	8 (17%)	
Mast Cell Tumor Malignant	1 (2%)			
Spleen	(49)	(50)	(49)	(50)
Hemangiosarcoma	4 (8%)	2 (4%)	2 (4%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 03038 - 04  
**Test Type:** CHRONIC  
**Route:** DOSED WATER  
**Species/Strain:** MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
**CAS Number:** 10213-10-2

**Date Report Requested:** 06/26/2019  
**Time Report Requested:** 10:46:08  
**First Dose M/F:** 01/17/12 / 01/16/12  
**Lab:** BAT

B6C3F1/N MICE MALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Histiocytic Sarcoma				1 (2%)
Lymphoma Malignant	4 (8%)		7 (14%)	
Thymus	(45)	(44)	(44)	(41)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)	1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Histiocytic Sarcoma				1 (2%)
Lymphoma Malignant	3 (7%)		4 (9%)	
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(1)	(2)	(2)	(4)
Skin	(50)	(50)	(50)	(50)
Pinna, Sarcoma			1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Schwannoma Malignant, Metastatic, Spinal Cord	1 (2%)			
Skeletal Muscle	(1)	(1)	(1)	(0)
Hemangiosarcoma	1 (100%)			
Hepatoblastoma, Metastatic, Liver			1 (100%)	
Hepatocellular Carcinoma, Metastatic, Liver		1 (100%)		
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Ependymoma Malignant			1 (2%)	
Schwannoma Malignant, Metastatic, Spinal Cord	1 (2%)			
Brain Trigeminal Ganglion	(0)	(0)	(1)	(0)
Peripheral Nerve	(0)	(0)	(1)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE MALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Spinal Cord Schwannoma Malignant	(1) 1 (100%)	(0)	(1)	(0)
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	5 (10%)	8 (16%)	7 (14%)	9 (18%)
Alveolar/Bronchiolar Adenoma, Multiple			2 (4%)	1 (2%)
Alveolar/Bronchiolar Carcinoma	1 (2%)	4 (8%)	2 (4%)	2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Carcinoma, Metastatic, Harderian Gland		1 (2%)		
Hemangiosarcoma		2 (4%)		
Hepatoblastoma, Metastatic, Liver			2 (4%)	
Hepatocellular Carcinoma, Metastatic, Liver	6 (12%)	11 (22%)	7 (14%)	1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		1 (2%)
Histiocytic Sarcoma	1 (2%)			1 (2%)
Lymphoma Malignant	2 (4%)		2 (4%)	
Pheochromocytoma Malignant, Metastatic, Adrenal Medulla				1 (2%)
Serosa, Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Nose	(50)	(50)	(50)	(50)
Schwannoma Malignant, Metastatic, Spinal Cord	1 (2%)			
Trachea	(50)	(50)	(50)	(50)
<b>SPECIAL SENSES SYSTEM</b>				
Ear	(1)	(0)	(0)	(0)
Eye	(50)	(50)	(50)	(50)
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	2 (4%)	1 (2%)	1 (2%)	6 (12%)
Carcinoma	1 (2%)	4 (8%)	2 (4%)	
Lymphoma Malignant	2 (4%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 03038 - 04  
**Test Type:** CHRONIC  
**Route:** DOSED WATER  
**Species/Strain:** MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
**CAS Number:** 10213-10-2

**Date Report Requested:** 06/26/2019  
**Time Report Requested:** 10:46:08  
**First Dose M/F:** 01/17/12 / 01/16/12  
**Lab:** BAT

B6C3F1/N MICE MALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Lymphoma Malignant	3 (6%)		2 (4%)	
Renal Tubule, Adenoma			1 (2%)	
Renal Tubule, Carcinoma				2 (4%)
Ureter	(1)	(0)	(0)	(0)
Urethra	(1)	(0)	(0)	(0)
Urinary Bladder	(50)	(50)	(50)	(50)
Lymphoma Malignant	2 (4%)		1 (2%)	
<b>SYSTEMIC LESIONS</b>				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Amyloid		1 (2%)		
Histiocytic Sarcoma	1 (2%)	1 (2%)		1 (2%)
Lymphoma Malignant	5 (10%)	1 (2%)	9 (18%)	
Mast Cell Tumor Malignant	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically



Experiment Number: 03038 - 04  
Test Type: CHRONIC  
Route: DOSED WATER  
Species/Strain: MICE/B6C3F1/N

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
Sodium Tungstate Dihydrate  
CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
Time Report Requested: 10:46:08  
First Dose M/F: 01/17/12 / 01/16/12  
Lab: BAT

---

B6C3F1/N MICE MALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
--------------------	--------	----------	-----------	-----------

---

### Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	42	47	44	44
Total Primary Neoplasms	80	89	88	68
Total Animals with Benign Neoplasms	31	32	36	34
Total Benign Neoplasms	37	42	47	42
Total Animals with Malignant Neoplasms	30	31	29	23
Total Malignant Neoplasms	43	47	41	26
Total Animals with Metastatic Neoplasms	7	14	11	3
Total Metastatic Neoplasms	11	23	13	9
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE FEMALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
<b>Disposition Summary</b>				
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	2	1	2	
Natural Death	10	8	10	10
Survivors				
Natural Death		1		
Terminal Sacrifice	38	40	38	40
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Lymphoma Malignant			1 (2%)	
Gallbladder	(48)	(50)	(47)	(50)
Lymphoma Malignant				1 (2%)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Lymphoma Malignant		1 (2%)		
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Lymphoma Malignant			1 (2%)	
Intestine Small, Duodenum	(49)	(50)	(50)	(49)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Lymphoma Malignant		1 (2%)	1 (2%)	
Intestine Small, Jejunum	(50)	(50)	(49)	(50)
Hemangiosarcoma			1 (2%)	
Lymphoma Malignant	1 (2%)	3 (6%)	3 (6%)	
Peyer's Patch, Histiocytic Sarcoma			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)			
Hemangiosarcoma		1 (2%)		
Hepatocellular Adenoma	6 (12%)	9 (18%)	4 (8%)	7 (14%)
Hepatocellular Adenoma, Multiple	5 (10%)	10 (20%)	7 (14%)	3 (6%)
Hepatocellular Carcinoma	2 (4%)	8 (16%)	3 (6%)	3 (6%)
Hepatocellular Carcinoma, Multiple			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE FEMALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Hepatocholangiocarcinoma				1 (2%)
Histiocytic Sarcoma	2 (4%)	1 (2%)	2 (4%)	
Lymphoma Malignant	2 (4%)	4 (8%)	4 (8%)	7 (14%)
Mesentery	(10)	(12)	(13)	(7)
Fibrous Histiocytoma		1 (8%)		
Fibrous Histiocytoma, Metastatic, Skin	1 (10%)			
Hemangiosarcoma			1 (8%)	
Histiocytic Sarcoma	1 (10%)		1 (8%)	
Lymphoma Malignant	1 (10%)	2 (17%)	2 (15%)	2 (29%)
Mesothelioma Malignant		1 (8%)		
Oral Mucosa	(1)	(0)	(1)	(0)
Pancreas	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)			
Hemangiosarcoma			1 (2%)	
Histiocytic Sarcoma	1 (2%)			
Lymphoma Malignant	2 (4%)	4 (8%)	3 (6%)	5 (10%)
Salivary Glands	(50)	(50)	(49)	(49)
Lymphoma Malignant	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Lymphoma Malignant		1 (2%)	2 (4%)	1 (2%)
Squamous Cell Papilloma			1 (2%)	
Squamous Cell Papilloma, Multiple	1 (2%)			
Stomach, Glandular	(50)	(50)	(50)	(50)
Hemangiosarcoma			1 (2%)	
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Tongue	(1)	(1)	(0)	(0)
Squamous Cell Papilloma	1 (100%)	1 (100%)		
Tooth	(2)	(5)	(2)	(1)

**CARDIOVASCULAR SYSTEM**

Blood Vessel	(47)	(50)	(49)	(50)
Heart	(50)	(50)	(50)	(50)
Histiocytic Sarcoma	1 (2%)		1 (2%)	
Lymphoma Malignant		1 (2%)	2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE FEMALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Pericardium, Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Pericardium, Liposarcoma, Metastatic, Skin	1 (2%)			

**ENDOCRINE SYSTEM**

Adrenal Cortex	(50)	(50)	(50)	(50)
Lymphoma Malignant Subcapsular, Adenoma		1 (2%)		1 (2%)
Adrenal Medulla	(50)	(50)	(50)	(49)
Islets, Pancreatic	(48)	(50)	(49)	(50)
Adenoma		1 (2%)	1 (2%)	
Carcinoma		1 (2%)		
Parathyroid Gland	(45)	(40)	(42)	(43)
Pituitary Gland	(50)	(50)	(47)	(50)
Hemangiosarcoma				1 (2%)
Pars Distalis, Adenoma	2 (4%)		5 (11%)	1 (2%)
Pars Distalis, Carcinoma		1 (2%)		
Thyroid Gland	(49)	(50)	(49)	(50)
Lymphoma Malignant			1 (2%)	
Follicular Cell, Adenoma				1 (2%)

**GENERAL BODY SYSTEM**

None

**GENITAL SYSTEM**

Clitoral Gland	(49)	(49)	(49)	(49)
Ovary	(49)	(49)	(50)	(50)
Cystadenoma	2 (4%)	1 (2%)	5 (10%)	4 (8%)
Cystadenoma, Multiple	1 (2%)			
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)			
Histiocytic Sarcoma	2 (4%)	1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE FEMALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Luteoma	1 (2%)			
Lymphoma Malignant	2 (4%)		2 (4%)	4 (8%)
Tubulostromal Adenoma		1 (2%)	1 (2%)	
Uterus	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)		1 (2%)	
Histiocytic Sarcoma	2 (4%)			
Leiomyosarcoma			1 (2%)	
Lymphoma Malignant	1 (2%)	1 (2%)	2 (4%)	3 (6%)
Polyp Stromal			2 (4%)	1 (2%)
Cervix, Histiocytic Sarcoma		1 (2%)	2 (4%)	
Vagina	(50)	(50)	(50)	(50)
Leiomyosarcoma				1 (2%)
Lymphoma Malignant		1 (2%)	2 (4%)	1 (2%)
Polyp			1 (2%)	

**HEMATOPOIETIC SYSTEM**

Bone Marrow	(48)	(50)	(49)	(48)
Hemangiosarcoma		1 (2%)	1 (2%)	
Histiocytic Sarcoma	2 (4%)	1 (2%)		
Lymphoma Malignant		3 (6%)	3 (6%)	4 (8%)
Lymph Node	(9)	(8)	(8)	(3)
Fibrous Histiocytoma		1 (13%)		
Histiocytic Sarcoma	2 (22%)	1 (13%)	2 (25%)	
Lymphoma Malignant	2 (22%)	5 (63%)	3 (38%)	3 (100%)
Lymph Node, Mandibular	(49)	(49)	(48)	(50)
Fibrous Histiocytoma		1 (2%)		
Histiocytic Sarcoma	2 (4%)	1 (2%)	1 (2%)	
Lymphoma Malignant	2 (4%)	5 (10%)	2 (4%)	4 (8%)
Lymph Node, Mesenteric	(49)	(49)	(49)	(50)
Fibrous Histiocytoma		1 (2%)		
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)			
Hemangiosarcoma			1 (2%)	
Histiocytic Sarcoma	2 (4%)	1 (2%)	1 (2%)	
Lymphoma Malignant	3 (6%)	7 (14%)	8 (16%)	7 (14%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 03038 - 04  
**Test Type:** CHRONIC  
**Route:** DOSED WATER  
**Species/Strain:** MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
**CAS Number:** 10213-10-2

**Date Report Requested:** 06/26/2019  
**Time Report Requested:** 10:46:08  
**First Dose M/F:** 01/17/12 / 01/16/12  
**Lab:** BAT

B6C3F1/N MICE FEMALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Spleen	(50)	(48)	(49)	(50)
Fibrous Histiocytoma		1 (2%)		
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)			
Hemangiosarcoma		1 (2%)		
Histiocytic Sarcoma	2 (4%)	1 (2%)		
Lymphoma Malignant	3 (6%)	10 (21%)	5 (10%)	7 (14%)
Thymus	(49)	(48)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Histiocytic Sarcoma	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Liposarcoma, Metastatic, Skin	1 (2%)			
Lymphoma Malignant	3 (6%)	6 (13%)	3 (6%)	4 (8%)

**INTEGUMENTARY SYSTEM**

Mammary Gland	(49)	(50)	(50)	(49)
Adenocarcinoma		1 (2%)		
Duct, Adenocarcinoma	1 (2%)			
Skin	(50)	(50)	(50)	(50)
Fibrosarcoma		1 (2%)	1 (2%)	
Fibrous Histiocytoma	1 (2%)	1 (2%)		1 (2%)
Liposarcoma	1 (2%)			
Lymphoma Malignant		1 (2%)	1 (2%)	
Melanoma Malignant			1 (2%)	
Sarcoma		1 (2%)		
Schwannoma Malignant			2 (4%)	

**MUSCULOSKELETAL SYSTEM**

Bone	(50)	(50)	(50)	(50)
Skeletal Muscle	(2)	(0)	(1)	(0)
Lymphoma Malignant	1 (50%)			
Sarcoma	1 (50%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE FEMALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
Schwannoma Malignant, Metastatic, Skin			1 (100%)	
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pituitary Gland		1 (2%)		
Histiocytic Sarcoma	1 (2%)			
Lymphoma Malignant		1 (2%)	2 (4%)	1 (2%)
Meninges, Hemangiosarcoma				1 (2%)
<b>RESPIRATORY SYSTEM</b>				
Larynx	(0)	(1)	(0)	(0)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	2 (4%)	2 (4%)		1 (2%)
Alveolar/Bronchiolar Carcinoma	1 (2%)	2 (4%)	5 (10%)	4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)	1 (2%)		1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site	1 (2%)			1 (2%)
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	3 (6%)	1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Histiocytic Sarcoma	2 (4%)	1 (2%)	2 (4%)	
Liposarcoma, Metastatic, Skin	1 (2%)			
Lymphoma Malignant	2 (4%)	2 (4%)	2 (4%)	4 (8%)
Osteosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Nose	(50)	(50)	(50)	(50)
Hemangioma				1 (2%)
Histiocytic Sarcoma		1 (2%)	1 (2%)	
Lymphoma Malignant			2 (4%)	
Trachea	(50)	(50)	(48)	(50)
Lymphoma Malignant			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03038 - 04  
 Test Type: CHRONIC  
 Route: DOSED WATER  
 Species/Strain: MICE/B6C3F1/N

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Sodium Tungstate Dihydrate  
 CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
 Time Report Requested: 10:46:08  
 First Dose M/F: 01/17/12 / 01/16/12  
 Lab: BAT

B6C3F1/N MICE FEMALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(48)	(50)
Histiocytic Sarcoma	1 (2%)			
Lymphoma Malignant			1 (2%)	
Harderian Gland	(50)	(50)	(48)	(50)
Adenoma	1 (2%)	5 (10%)	1 (2%)	2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)	1 (2%)
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Histiocytic Sarcoma	2 (4%)	1 (2%)	1 (2%)	
Lymphoma Malignant	2 (4%)	5 (10%)	3 (6%)	7 (14%)
Urinary Bladder	(50)	(50)	(49)	(50)
Histiocytic Sarcoma		1 (2%)		
Lymphoma Malignant	2 (4%)	1 (2%)	2 (4%)	2 (4%)
<b>SYSTEMIC LESIONS</b>				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Lymphoma Malignant	4 (8%)	13 (26%)	8 (16%)	9 (18%)
Mesothelioma Malignant		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically



Experiment Number: 03038 - 04  
Test Type: CHRONIC  
Route: DOSED WATER  
Species/Strain: MICE/B6C3F1/N

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
Sodium Tungstate Dihydrate  
CAS Number: 10213-10-2

Date Report Requested: 06/26/2019  
Time Report Requested: 10:46:08  
First Dose M/F: 01/17/12 / 01/16/12  
Lab: BAT

---

B6C3F1/N MICE FEMALE	0 mg/L	500 mg/L	1000 mg/L	2000 mg/L
----------------------	--------	----------	-----------	-----------

---

### Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	31	36	40	27
Total Primary Neoplasms	38	71	60	44
Total Animals with Benign Neoplasms	20	24	23	16
Total Benign Neoplasms	23	31	28	21
Total Animals with Malignant Neoplasms	14	27	23	19
Total Malignant Neoplasms	15	40	32	23
Total Animals with Metastatic Neoplasms	4	4	3	2
Total Metastatic Neoplasms	16	4	3	3
Total Animals with Malignant Neoplasms Uncertain Primary Site	1		1	1
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors